top space
bottom spacer
Home > Investors > Press Releases

Press Releases

Learn more about exciting new happenings at Echo Therapeutics. Click on the latest news releases below or scan through the archives.

 

08/14/2014 3:30 pm
Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update

40%-50% Monthly Cash Burn Reduction Initiatives Implemented

Increased Focus on Key Symphony CGM System Enhancements

Aug 14, 2014

PHILADELPHIA, Aug. 14, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced its financial results for the quarter ended June 30, 2014 and provided a business update.  Echo's Quarterly Report on Form 10…… Read More

06/19/2014 3:07 pm
Echo Announces Election Of New Board Member At Annual Meeting Of Stockholders

06/11/2014 6:50 am
Echo Mails Letter To Stockholders

Letter Urges Stockholders to Follow the Recommendations of the Three Leading Proxy Advisory Firms and Vote the White Proxy Card to Re-elect Robert F. Doman to the Board

06/09/2014 6:50 am
Leading Independent Proxy Advisory Firm Egan-Jones Joins ISS And Glass Lewis In Recommending That Echo Stockholders Reject Platinum's Board Nominee Shepard Goldberg And Vote The WHITE Proxy Card

All Three Leading Independent Proxy Advisory Firms Now Recommend That Stockholders Vote FOR Echo's Board Nominees

06/06/2014 2:07 pm
Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis In Recommending That Echo Stockholders Reject Platinum's Board Nominee Shepard Goldberg And Vote The WHITE Proxy Card

Both Leading Independent Proxy Advisory Firms Now Recommend That Stockholders Vote FOR Echo's Board Nominees

06/05/2014 6:50 am
Positive Clinical Trial Results of Echo Therapeutics Symphony CGM System to be Presented at the 74th Scientific Sessions of the American Diabetes Association

PHILADELPHIA, June 5, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring sy…… Read More

06/05/2014 3:17 pm
Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Stockholders Vote The WHITE Proxy Card FOR Echo's Board Nominees

06/03/2014 6:23 pm
Echo Mails Letter To Stockholders

Letter Questions Whether Platinum Group Can be Trusted to Protect the Interests of Stockholders

Recommends Stockholders Vote Revised White Proxy Card

05/30/2014 6:50 am
Echo Therapeutics to File Investor Presentation

Echo Urges Stockholders to Elect Incumbent Directors and Reject Platinum Group's Slate

Recommends Stockholders Vote Revised White Proxy Card

05/27/2014 8:01 am
Echo Mails Letter To Stockholders

Letter Questions Qualifications of Platinum Group's Board Nominee

Recommends Stockholders Vote Revised White Proxy Card

05/22/2014 6:50 am
Echo Mails Letter To Stockholders

Letter Questions Platinum Group's Agenda for Waging Costly & Distracting Proxy Contest

Recommends Stockholders Vote Revised White Proxy Card

05/16/2014 3:45 pm
Echo Mails Letter To Stockholders

Letter Highlights Stark Difference Between Echo's Board Slate and Platinum's Board Slate

Recommends Stockholders Vote Revised White Proxy Card

05/12/2014 6:55 am
Echo Therapeutics Files Definitive Proxy Materials

Recommends Stockholders Vote Revised White Proxy Card

05/09/2014 6:50 am
Echo Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Regulatory and Product Development Update

Company to Host Conference Call Today, May 9, 2014 at 9:00 AM EDT

05/08/2014 6:50 am
Echo Therapeutics Schedules First Quarter 2014 Financial Results and Regulatory and Product Development Update for Friday, May 9, 2014

Conference Call to begin at 9:00 a.m. EDT

PHILADELPHIA, May 8, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless c…… Read More

04/29/2014 3:35 pm
Echo Therapeutics Mails Letter To Stockholders; Urges Stockholders Not To Vote Platinum's Gold Proxy Card

04/24/2014 10:45 am
Echo Therapeutics Files Preliminary Proxy Materials In Connection With 2014 Annual Meeting Of Stockholders

04/22/2014 4:30 pm
Echo Therapeutics Comments on Proxy Contest by Platinum Management (NY) LLC

03/27/2014 6:50 am
Echo Therapeutics, Inc. Announces 2013 Financial Results

Company to Host Conference Call Today, March 27, 2014 at 9:00 AM ET

03/20/2014 8:35 am
Echo Therapeutics Schedules 2013 Financial Results for Thursday, March 27, 2014

Conference Call to begin at 9:00 a.m. ET

PHILADELPHIA, Pa., March 20, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wir…… Read More

03/06/2014 6:50 am
Echo Therapeutics to Exhibit at the ISICEM 2014 Critical Care Conference

PHILADELPHIA, March 6, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring s…… Read More

03/03/2014 6:50 am
Echo Therapeutics to Present at the 26th Annual ROTH Capital Conference

PHILADELPHIA, March 3, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring s…… Read More

02/28/2014 6:50 am
Echo Therapeutics Adds New Member to Board of Directors

PHILADELPHIA, Feb. 28, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring sy…… Read More

02/06/2014 6:50 am
Echo Therapeutics to Participate in the Leerink Swann 2014 Global Healthcare Conference

PHILADELPHIA, Feb. 6, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring sy…… Read More

01/15/2014 6:50 am
Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference

PHILADELPHIA, Jan. 15, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring s…… Read More

01/14/2014 6:50 am
Echo Therapeutics Hires Product Development Management Executive

PHILADELPHIA, Jan. 14, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring sy…… Read More

01/13/2014 7:54 am
Echo Therapeutics Submits CE Mark Technical File for its Symphony® CGM System

PHILADELPHIA, Jan. 13, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring s…… Read More

12/10/2013 4:42 pm
Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA)

Echo to receive a $10 million cash investment from MTIA and Platinum Partners

Company will withdraw the offering identified in recent Form S-1 filing

PHILADELPHIA, Dec. 10, 2013 /PRNewswire/ -- Echo Therapeutics, I…… Read More

11/26/2013 6:50 am
Echo Therapeutics Announces Positive CE Mark Regulatory Trial Results of Symphony® CGM System

Symphony meets primary safety and effectiveness endpoints

Company on target to file CE Mark Technical File by year end

PHILADELPHIA, Nov. 26, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medica…… Read More

11/25/2013 3:55 pm
Echo Therapeutics Schedules Release of Symphony® CGM System CE Mark Regulatory Trial Results for Tuesday, November 26, 2013

Conference Call to begin at 9:00 a.m. ET

PHILADELPHIA, Nov. 25, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wirele…… Read More

11/07/2013 6:50 am
Echo Therapeutics Announces Third Quarter 2013 Financial Results

Company to Host Conference Call Today, November 7, 2013 at 9:00 AM EST

11/01/2013 8:27 am
Echo Therapeutics Schedules Third Quarter 2013 Financial Results for Thursday, November 7, 2013

Conference Call to begin at 9:00 a.m. ET

PHILADELPHIA, Nov. 1, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wirele…… Read More

10/03/2013 6:50 am
Echo Therapeutics Provides Corporate Update and Implements Substantial Cost Reduction Initiatives

PHILADELPHIA, Oct. 3, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless, continuous glucose monitoring system, …… Read More

09/05/2013 6:50 am
Echo Therapeutics Sends Response to Shareholder Letter

PHILADELPHIA, Sept. 5, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its needle-free Symphony® CGM System as a non-invasive, wireless, continuous glucose monito…… Read More

08/08/2013 6:50 am
Echo Therapeutics Announces Second Quarter 2013 Financial Results

08/06/2013 6:50 am
Echo Therapeutics Schedules Second Quarter 2013 Financial Results for Thursday, August 8, 2013

Conference Call to begin at 9:00 a.m. ET

PHILADELPHIA, Aug. 6, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its non-invasive Symphony® CGM System as a needle-free, wireless c…… Read More

07/03/2013 6:50 am
Echo Therapeutics Provides Mid-Year Update to Shareholders

Company Streamlines Cost Structure with Focus on Achieving Critical Milestones

PHILADELPHIA, July 3, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its non-invasive Symphony® C…… Read More

06/26/2013 6:50 am
Echo Therapeutics Regains Compliance with Nasdaq Listing Requirements

PHILADELPHIA, June 26, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, toda…… Read More

06/19/2013 3:15 pm
Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter

PHILADELPHIA, June 19, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, tod…… Read More

06/13/2013 6:30 pm
Echo Therapeutics Announces Pricing of Public Offering of Common Stock

PHILADELPHIA, June 13, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, tod…… Read More

06/10/2013 6:50 am
Echo Therapeutics Submits Pre-Submission Package to FDA for Symphony® CGM System

PHILADELPHIA, June 10, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, tod…… Read More

06/06/2013 3:30 pm
Echo Therapeutics Announces Reverse Split of Common Stock

Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on June 7, 2013

PHILADELPHIA, June 6, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony…… Read More

06/05/2013 6:50 am
Echo Therapeutics Initiates CE Mark Clinical Trial of its Symphony® CGM System

PHILADELPHIA, June 5, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, toda…… Read More

05/30/2013 6:50 am
Echo Therapeutics to Present at the Jefferies Global Healthcare Conference

PHILADELPHIA, May 30, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring…… Read More

05/29/2013 6:50 am
Notified Body Accepts Echo Therapeutics' Clinical Trial Plan for Symphony® CGM System

Data from the trial will support CE Marking

PHILADELPHIA, May 29, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireles…… Read More

05/23/2013 1:28 pm
Echo Therapeutics Announces Successful Unveiling of Symphony® CGM System

Demonstration Followed Stockholders Approval of All Resolutions at Annual Meeting

PHILADELPHIA, May 23, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony®…… Read More

05/21/2013 6:50 am
Echo Therapeutics Announces Institutional Review Board (IRB) Approval for Its Clinical Trial of the Symphony® CGM System

PHILADELPHIA, May 21, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring…… Read More

05/16/2013 6:50 am
Echo Therapeutics to Unveil Symphony® CGM System in Webcast

Demonstration coincides with Symphony's upcoming CE Mark pivotal trial

PHILADELPHIA, May 16, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System …… Read More

05/10/2013 6:50 am
Echo Therapeutics Announces First Quarter 2013 Financial Results

PHILADELPHIA, May 10, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring…… Read More

03/18/2013 6:50 am
Echo Therapeutics, Inc. Announces 2012 Financial Results

PHILADELPHIA, March 18, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More

03/15/2013 6:50 am
Echo Therapeutics Achieves ISO 13485 Certification

PHILADELPHIA, March 15, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More

03/13/2013 6:50 am
Echo Therapeutics Appoints Robert Doman to Board of Directors

PHILADELPHIA, March 13, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More

03/12/2013 6:50 am
Echo Therapeutics Granted U.S. Patent for Prelude® SkinPrep System

PHILADELPHIA, March 12, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More

02/06/2013 11:00 am
Echo Therapeutics Announces Closing of Public Offering of Common Stock

PHILADELPHIA, Feb. 6, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose…… Read More

01/31/2013 7:26 pm
Echo Therapeutics Announces Pricing of Public Offering of Common Stock

PHILADELPHIA, Jan. 31, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More

01/31/2013 3:05 pm
Echo Therapeutics Announces Proposed Public Offering

PHILADELPHIA, Jan. 31, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More

01/22/2013 6:50 am
Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony® tCGM System at the 42nd Critical Care Congress

PHILADELPHIA, Jan. 22, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wirel…… Read More

01/22/2013 6:50 am
Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony® tCGM System at the 42nd Critical Care Congress

PHILADELPHIA, Jan. 22, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wirel…… Read More

01/22/2013 6:50 am
Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony® tCGM System at the 42nd Critical Care Congress

PHILADELPHIA, Jan. 22, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wirel…… Read More

01/15/2013 6:50 am
Echo Therapeutics to Present at the Noble Financial Capital Markets' Ninth Annual Equity Conference

PHILADELPHIA, Jan. 15, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More

01/07/2013 6:50 am
Echo Therapeutics, Inc. (Nasdaq: ECTE) Provides an Update to Shareholders

2013 Shaping Up To Be Dynamic Year With Numerous Anticipated Milestones

PHILADELPHIA, Jan. 7, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony…… Read More

12/27/2012 6:50 am
Echo Therapeutics to Present at Biotech Showcase 2013 in San Francisco

PHILADELPHIA, Dec. 27, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More

12/27/2012 3:15 pm
Echo Therapeutics Announces Closing of Public Offering of Common Stock

PHILADELPHIA, Dec. 27, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring syste…… Read More

12/26/2012 3:15 pm
Echo Therapeutics Announces Full Exercise of Over-Allotment Option

PHILADELPHIA, Dec. 26, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More

12/20/2012 7:22 pm
Echo Therapeutics Announces Pricing of Public Offering of Common Stock

PHILADELPHIA, Dec. 20, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More

12/20/2012 3:24 pm
Echo Therapeutics Announces Proposed Public Offering

PHILADELPHIA, Dec. 20, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today a…… Read More

12/12/2012 6:50 am
Echo Therapeutics to Present Clinical Study Results of Symphony® tCGM System at the 42nd Critical Care Congress

PHILADELPHIA, Dec. 12, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, is ple…… Read More

11/29/2012 6:50 am
Echo Therapeutics to Present at the Canaccord Genuity 2012 Medical Technology & Diagnostics Forum

PHILADELPHIA, Nov. 29, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More

11/29/2012 6:30 am
Echo Therapeutics Announces Withdrawal of Proposed Follow-On Offering

PHILADELPHIA, Nov. 29, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system,…… Read More

11/27/2012 3:15 pm
Echo Therapeutics Announces Proposed Public Offering

PHILADELPHIA, Nov. 27, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More

11/19/2012 6:50 am
Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain

Johnson & Johnson Executive Brings Nearly 30 Years of Supply Chain Leadership

PHILADELPHIA, Nov. 19, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a n…… Read More

11/09/2012 6:50 am
Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting

PHILADELPHIA, Nov. 9, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today a…… Read More

11/08/2012 6:50 am
Echo Therapeutics Announces Third Quarter 2012 Financial Results

Company to Host Conference Call Today, November 8, 2012 at 9:00 AM EST

PHILADELPHIA, Nov. 8, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® t…… Read More

09/04/2012 6:50 am
Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference

PHILADELPHIA, Sept. 4, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics, will present at the Rodman & Renshaw Annual Global Investment Conference.

(Logo: http://photos.prnewswire.com/…… Read More

08/10/2012 6:50 am
Echo Therapeutics Announces Second Quarter 2012 Financial Results

PHILADELPHIA, Aug. 10, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the quarter ended June 30, 2012. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available through Echo's website at www.echotx.com.

(Logo: h…… Read More

08/09/2012 7:00 am
Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences

Commitment provides resources to move Symphony® tCGM System toward regulatory clearance

PHILADELPHIA, Aug. 9, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Platinum-Montaur Life Sciences, LLC (Montaur) will provide Echo a credit facility of up …… Read More

08/01/2012 6:50 am
Echo Therapeutics Announces Positive Clinical Trial Results of Symphony® tCGM System

Data demonstrate that Symphony accurately monitors glucose levels in hospital patients

PHILADELPHIA, Aug. 1, 2012 /PRNewswire/ --  Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical trial of the Symphony tCGM System in major general surgery…… Read More

07/11/2012 7:04 am
Echo Therapeutics Expands License Agreement with Ferndale Pharma

PHILADELPHIA, July 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that it signed an amended license agreement with Ferndale Pharma Group, Inc. ("Ferndale") that grants Ferndale the right to develop, market and sell Prelude for painless,…… Read More

06/20/2012 6:55 am
Echo Therapeutics Announces Patents for Symphony® tCGM System and Prelude® SkinPrep System

PHILADELPHIA, June 20, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced the receipt of a notice of allowance for a patent application covering its Prelude SkinPrep System and a notice of issuance for a patent covering its Symphony tCGM System.

Echo Th…… Read More

06/13/2012 6:55 am
Echo Therapeutics Set to Join the Russell Microcap® Index

PHILADELPHIA, June 13, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that, according to a preliminary list of additions posted on June 8, 2012 on www.russell.com, it expects to be included in the Russell Microcap® Index when Russell Investm…… Read More

06/12/2012 7:04 am
Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony® tCGM System at the American Diabetes Association's 72nd Scientific Sessions

PHILADELPHIA, June 12, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, presented an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during its recent clinical trial of its Symphony tCGM System.  The data were presented during a…… Read More

05/30/2012 7:00 am
Echo Therapeutics Hires Marketing Executive

Company continues to move Symphony® tCGM System toward commercialization

PHILADELPHIA, May 30, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that David Walton, who has nearly two decades of strategic healthcare marketing experience, has joined Echo…… Read More

05/29/2012 7:00 am
Echo Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference

PHILADELPHIA, May 29, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics will present at the Jefferies 2012 Global Healthcare Conference.

Dr. Mooney will make a corporate presentation t…… Read More

05/11/2012 7:00 am
Echo Therapeutics Announces First Quarter 2012 Financial Results

PHILADELPHIA, May 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the quarter ended March 31, 2012.  Echo's Quarterly Report on Form 10-Q as filed with the SEC is available through Echo's website at www.echotx.com.

Recent C…… Read More

05/08/2012 7:07 am
Echo Therapeutics Symphony® tCGM System To Be Profiled on The Doctors Television Show

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that CEO, Patrick T. Mooney, M.D. will appear on the Wednesday, May 9th airing of the popular Emmy Award-winning television show The Doctors.

Dr. Mooney discusses the benefi…… Read More

05/02/2012 7:00 am
Echo Therapeutics Announces Positive Clinical Trial Results of Symphony® tCGM System

PHILADELPHIA, May 2, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical trial of the Symphony tCGM System in elective cardiac surgery patients.  This study is the first of two studies Echo is conducting in critically i…… Read More

04/05/2012 7:00 am
Echo Therapeutics Announces Key Patents Covering Its Prelude® SkinPrep System and Symphony® tCGM System

PHILADELPHIA, April 5, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced the issuance of patents covering its Prelude SkinPrep System and a notice of allowance for a U.S. patent covering its Symphony tCGM System.

Patents entitled "Skin Permeation Devic…… Read More

04/02/2012 7:00 am
Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association

PHILADELPHIA, April 2, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, is pleased to announce that its most recently completed clinical trial was selected for presentation at the 72nd Scientific Sessions of the American Diabetes Association (ADA) which will be held Ju…… Read More

03/16/2012 7:00 am
Echo Therapeutics, Inc. Announces 2011 Financial Results

PHILADELPHIA, March 16, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the year ended December 31, 2011.  Echo's Annual Report on Form 10-K is available through Echo's website at www.echotx.com.

2011 Corporate Highlights:

01/24/2012 7:16 am
Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients

PHILADELPHIA, Jan. 24, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating clinical studies of its Symphony tCGM System in critical care patients. The company expects to complete and announce the results of the studies in the near term.

…… Read More

01/11/2012 7:52 am
Echo Therapeutics to Present at the Noble Financial Capital Markets' Eighth Annual Equity Conference

PHILADELPHIA, Jan. 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at Noble Financial Capital Markets' Eighth Annual Equity Conference.

Dr. Mooney will make a presenta…… Read More

01/04/2012 7:06 am
Echo Therapeutics Announces $3.6 Million Warrant Exercises

Cash position at year-end approximately $9.2 million

PHILADELPHIA, Jan. 4, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it has received warrant exercises generating a total of approximately $3.6 million in cash proceeds.  These warrant exercises bring the company's year-end cash balance to approximately $9.2 million.

"This cash infusion, following the recent positive clinical results for use of our Symphony System, represents impor…… Read More

01/03/2012 6:30 am
Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco

PHILADELPHIA, Jan. 3, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at the Biotech Showcase 2012 Conference.

Dr. Mooney will make a presentation to prospective c…… Read More

12/07/2011 6:30 am
Echo Therapeutics to Present at the Oppenheimer Healthcare Conference

PHILADELPHIA, Dec. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at the Oppenheimer 22nd Annual Healthcare Conference.

Dr. Mooney will make a presentation to …… Read More

12/06/2011 7:00 am
Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes

PHILADELPHIA, Dec. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical study of its Symphony tCGM System in patients with type 1 and type 2 diabetes.  Data from the study confirm that Symphony successfully monitors t…… Read More

12/06/2011 6:30 am
Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing

PHILADELPHIA, Dec. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced a registered direct equity financing of approximately $5.4 million by issuing units, with each unit consisting of one share of its common stock and a warrant to purchase 0.4 of a share o…… Read More

11/15/2011 6:30 am
Echo Therapeutics Announces $2 Million Warrant Exercise Commitment

PHILADELPHIA, Nov. 15, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it has received a commitment by its largest shareholder, Platinum Partners, for a warrant exercise of $2 million.  This warrant exercise will be in addition to the previously announced $1.7 million warrant exercise by Platinum.

"We are very pleased with this warrant exercise as it will allow us to continue the accelerated pace of product development finalization and clinical v…… Read More

11/08/2011 8:24 am
Echo Therapeutics Announces Third Quarter 2011 Financial Results

Company Continues Steady Progress Toward its Clinical and Operational Objectives

PHILADELPHIA, Nov. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, announced results for the third quarter and nine months ended September 30, 2011.  Echo's Quarterly Report on Form 10-Q i…… Read More

11/02/2011 6:40 am
Echo Therapeutics Announces Warrant Exercise by Its Largest Shareholder

Obligation to Redeem Series B Preferred Stock Eliminated

PHILADELPHIA, Nov. 2, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, announced that the Company entered into an agreement with its largest shareholder, Platinum Partners, in which Platinum exercised warrants with an…… Read More

10/13/2011 6:30 am
Echo Therapeutics Initiates Clinical Trial of its Symphony tCGM System in Patients with Type 1 and Type 2 Diabetes

PHILADELPHIA, Oct. 13, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 diabetes. The company expects to complete and announce the results of the study in t…… Read More

10/11/2011 6:30 am
Echo Therapeutics Hires Product Development Management Executive

PHILADELPHIA, Oct. 11, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that Samir Farah, who has more than fifteen years of medical product design and development experience, has joined Echo Therapeutics' management team at a critical stage in product devel…… Read More

10/06/2011 6:30 am
Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System

PHILADELPHIA, Oct. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical study of its Symphony tCGM System.  Data from the study confirm that Symphony successfully monitors patient glucose levels and continues to demonstrate i…… Read More

09/20/2011 6:30 am
Echo Therapeutics to Present at the JMP Securities Healthcare Conference

PHILADELPHIA, Sept. 20, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Sixth Annual JMP Securities Healthcare Conference.

Dr. Mooney will m…… Read More

09/15/2011 6:30 am
Echo Therapeutics Receives Registered Trademarks for Symphony® and Prelude®

Achievement marks important step in the commercialization of the products

PHILADELPHIA, Sept. 15, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that the company has received Certificates of Registration from the United States Patent and Tradem…… Read More

09/08/2011 7:00 am
Echo Therapeutics Initiates Clinical Trial of its Symphony Continuous Glucose Monitoring System

PHILADELPHIA, Sept. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System. The company expects to complete and announce the results of the study in the near-term.

"Initiating the clinical stu…… Read More

09/08/2011 7:00 am
Echo Therapeutics Initiates Clinical Trial of its Symphony Continuous Glucose Monitoring System

PHILADELPHIA, Sept. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System. The company expects to complete and announce the results of the study in the near-term.

"Initiating the clinical stu…… Read More

09/07/2011 7:00 am
Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference

PHILADELPHIA, Sept. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Rodman & Renshaw Annual Global Investment Conference.

Dr. Mooney wi…… Read More

08/31/2011 7:00 am
Echo Therapeutics to Present at the Stifel Nicolaus Healthcare Conference 2011

PHILADELPHIA, Aug. 31, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Stifel Nicolaus Healthcare Conference 2011.

Dr. Mooney will make a …… Read More

08/12/2011 7:00 am
Echo Therapeutics Announces Second Quarter 2011 Financial Results

Company remains focused on product advancement

PHILADELPHIA, Aug. 12, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the period ended June 30, 2011. Echo's Quarterly Report on Form 10-Q is available through Echo's website at w…… Read More

08/09/2011 7:00 am
Echo Therapeutics Unveils Symphony tCGM Demonstration Video

PHILADELPHIA, Aug. 9, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the unveiling of a much anticipated demonstration video on the Company's website at www.echotx.com.  The new video showcases the features and ease of use of the Symphony continuous glu…… Read More

08/08/2011 7:00 am
Echo Therapeutics Announces Multiple Patents and Trademark Grants

PHILADELPHIA, Aug. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the receipt of notices of issuance for two patents covering its Symphony tCGM System and notices of registration for the trademarks PRELUDE and SYMPHONY.

Echo Therapeutics received noti…… Read More

08/02/2011 7:00 am
Echo Therapeutics Hires Seasoned Diabetes Management Executive

Company Continues to Add Depth to Senior Management

PHILADELPHIA, Aug. 2, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that Marshall ('Mac') D. Deweese, who has more than fifteen years of experience in blood glucose monitoring systems, has joined Echo …… Read More

06/28/2011 6:30 am
Echo Therapeutics Announces NASDAQ Listing

Shares to begin trading on Wednesday, June 29, 2011

PHILADELPHIA, June 28, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market.

Echo expects its shares to begin trad…… Read More

06/03/2011 7:30 am
Echo Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference

PHILADELPHIA, June 3, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Jefferies 2011 Global Healthcare Conference.

Dr. Mooney will make a c…… Read More

05/23/2011 7:00 am
Echo Therapeutics Announces Symphony™ tCGM System Progress

PHILADELPHIA, May 23, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced that it has received the key components of its next generation Symphony tCGM System design.  This newly-engineered design is currently undergoing its final functionality testing.

The updated …… Read More

05/16/2011 7:30 am
Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer

He joins Patrick T. Mooney, CEO, and Harry G. Mitchell, COO, on the management team as the company expands

PHILADELPHIA, May 16, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that Christopher P. Schnittker, CPA, joined the company as its Chief Financial …… Read More

05/16/2011 7:00 am
Echo Therapeutics Announces First Quarter 2011 Financial Results

Company begins 2011 poised to accelerate growth

PHILADELPHIA, May 16, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC BB: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the period ended March 31, 2011.  Echo's Quarterly Report on Form 10-Q is available through Echo's website at ww…… Read More

05/10/2011 7:30 am
Echo Therapeutics to Present at the Noble Financial Capital Markets' Seventh Annual Equity Conference

FRANKLIN, Mass., May 10, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at SEVEN; Noble Financial Markets' Seventh Annual Equity Conference.

Dr. …… Read More

05/05/2011 7:30 am
Echo Therapeutics Expands Into New Headquarters in Philadelphia

PHILADELPHIA, May 5, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the relocation of its corporate headquarters from Franklin, MA to Philadelphia, PA.

The new office is located in the heart of Philadelphia's Center City Business District at 8 Penn Center…… Read More

04/12/2011 7:30 am
Echo Therapeutics Announces Patent for Symphony™ tCGM System

FRANKLIN, Mass., April 12, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it received a notice of allowance for U.S. Patent Application No.11/275,038, "System and Method for Continuous Non-Invasive Glucose Monitoring," for the Symphony tCGM System. …… Read More

03/22/2011 7:30 am
Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives

FRANKLIN, Mass., March 22, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that John Garibotto and Kenneth Gary, who collectively have nearly fifty years of medical device and diagnostics experience, have joined Echo Therapeutics' senior manag…… Read More

03/21/2011 7:30 am
Echo Therapeutics Announces 2010 Financial Results

Company begins 2011 poised to achieve national listing and product revenue

FRANKLIN, Mass., March 21, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the year ended December 31, 2010.  Echo's Annual Report on Form 10-K…… Read More

03/10/2011 7:30 am
Echo Therapeutics to Present at the ROTH 23rd Annual Growth Stock Conference

FRANKLIN, Mass., March 10, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the ROTH 23rd Annual Growth Stock Conference.

Dr. Moone…… Read More

03/01/2011 7:30 am
Echo Therapeutics Receives Frost & Sullivan's 2011 Technology Innovation Award

FRANKLIN, Mass., March 1, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it won the prestigious 2011 North American Frost & Sullivan Technology Innovation Award in Pharmaceuticals and Biotechnology.  Echo received this award in recognit…… Read More

02/17/2011 7:30 am
Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule

FRANKLIN, Mass., Feb. 17, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced that development of the commercially ready Symphony tCGM System is ahead of schedule.  The company said that the system will be ready for demonstration in the second quarter …… Read More

02/15/2011 7:30 am
Echo Therapeutics Announces Appointments to Board of Directors

New Directors Bring Over 60 Years of Commercial Healthcare Industry Experience

Board Considered Independent for National Exchange Listing

FRANKLIN, Mass., Feb. 15, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the appointment of William F. G…… Read More

02/10/2011 7:30 am
Echo Therapeutics' Needle-Free Prelude™ Drug Delivery System Is Featured in Fast Company Magazine

FRANKLIN, Mass., Feb. 10, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that its needle-free drug delivery device, the Prelude System, is featured on the Fast Company magazine website.

The article headlined, "New Drug Delivery Device Will Speed Up…… Read More

02/08/2011 7:30 am
Echo Therapeutics Announces Commercial Launch of Prelude™ on Track

Company Receives Comments From FDA That Are Consistent With Expectations

Plans National Exchange Listing and Anticipates Revenue in Third Quarter

FRANKLIN, Mass., Feb. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that the Company's partn…… Read More

01/25/2011 7:00 am
Echo Therapeutics Launches Corporate Twitter Account and Facebook Page

FRANKLIN, Mass., Jan. 25, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that the company has launched a corporate Twitter account and corporate Facebook Page.  Twitter users can now follow Echo at http://www.twitter.com/echotx and Face…… Read More

01/11/2011 7:00 am
Echo Therapeutics' Symphony™ System for Needle-Free Continuous Glucose Monitoring is Highlighted in Assembly Magazine's January 2011 Issue

FRANKLIN, Mass., Jan. 11, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that its Symphony System was featured in the cover story of Assembly Magazine's January 2011 issue.

"We are pleased to have our Symphony System profiled by Assembl…… Read More

01/07/2011 7:00 am
Echo Therapeutics to Present at the OneMedForum 2011 Conference

FRANKLIN, Mass., Jan. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the OneMedForum 2011 annual healthcare conference held Ja…… Read More

01/06/2011 7:00 am
Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million

Company Anticipates Funding is Sufficient Through Symphony Glucose Monitor Pivotal Study

FRANKLIN, Mass., Jan. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that it has raised approximately $2.5 million through a series of private pl…… Read More

01/05/2011 7:00 am
Echo Therapeutics to Present at the Biotech Showcase 2011 Conference

FRANKLIN, Mass., Jan. 5, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Biotech Showcase 3rd Annual Healthcare Conference hel…… Read More

11/30/2010 11:13 am
Echo Therapeutics' Needle-Free Symphony Continuous Glucose Monitoring System Featured in Diabetes Health Magazine

November 29 Issue Profiles Echo's Much-Needed Technology for Continuous Monitoring

FRANKLIN, Mass., Nov. 30, 2010 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that its Symphony System was profiled in the November 29, 2010 issue of Diabete…… Read More

11/11/2010 7:00 am
Echo Therapeutics Announces Filing of 510(k) Submission Seeking Market Clearance from FDA for its Prelude SkinPrep System and 4% Lidocaine Cream

FRANKLIN, Mass., Nov. 11, 2010 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that a 510(k) premarket notification has been submitted to the US Food and Drug Administration (FDA) for its Prelude SkinPrep System and 4% lidocaine cream.  Marke…… Read More

11/04/2010 7:00 am
Echo Therapeutics Awarded Section 48D Grant of up to $500,000

Company expects 510k application for Prelude to be filed in the near-term

FRANKLIN, Mass., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that it has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant …… Read More

10/29/2010 8:19 am
Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference

FRANKLIN, Mass., Oct. 29 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the LifeTech Capital 1st Annual Miami Medical Investors Confer…… Read More

09/23/2010 8:09 am
Echo Therapeutics to Present at the JMP Securities Healthcare Conference

FRANKLIN, Mass., Sept. 23 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the JMP Securities Healthcare Conference being held September…… Read More

09/21/2010 7:37 am
Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring

Adds Additional Market Opportunities to Company's Platform Technology; Feasibility Studies Indicate Success in Humans

FRANKLIN, Mass., Sept. 21 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that it is beginning a development progra…… Read More

09/16/2010 7:31 am
Echo Therapeutics to Present at Prestigious Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference

FRANKLIN, Mass., Sept. 16 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick Mooney, M.D., Echo's Chairman and Chief Executive Officer, will present at the prestigious Accredited Members, Inc. (AMI) Fall 2010 Small Cap/Micro Cap Inve…… Read More

08/24/2010 7:00 am
Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream

FRANKLIN, Mass., Aug. 24 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced the completion of a clinical study of Prelude. This clinical study was designed to evaluate the ability of Prelude to ablate the skin prior to the application o…… Read More

05/21/2010 12:07 pm
Echo Therapeutics Needle-Free Symphony™ tCGM System and Prelude™ SkinPrep System Featured in LifeTech Capital Audio Interview

Chairman of Echo Therapeutics Scientific Advisory Board, Dr. Robert Langer, discusses the Company's Technology and Products

FRANKLIN, Mass., May 21 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that the Chairman of its Scien…… Read More

05/17/2010 4:31 pm
Echo Therapeutics Announces First Quarter 2010 Financial Results

Company begins transformative 2010 poised to grow revenue and achieve national listing

FRANKLIN, Mass., May 17 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced financial results for the period ended March 31, 2010.

Recent Co…… Read More

04/27/2010 12:00 am
Echo Therapeutics and Ferndale Pharma Group Initiate Clinical Trial for Prelude(TM) SkinPrep Device and 4% Lidocaine Cream
Milestone Event Validates Expectations of Near-Term Filing for FDA Clearance and Subsequent Launch

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, in collaboration with its strategic partner, Ferndale Pharma Group, Inc., announced today that the first patients were enrolled in a clinical study of its Prelude SkinPrep System. This clinical study is designed to evalu…… Read More

04/05/2010 12:00 am
Echo Therapeutics Needle-Free Symphony(TM) tCGM System Featured in Scientific American Magazine Article
Article Discusses the Importance of Continuous Glucose Monitoring

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that its Symphony(TM) tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasiv…… Read More

04/02/2010 12:00 am
Echo Therapeutics Needle-Free Symphony(TM) tCGM System Featured in Scientific American Magazine Article
Article Discusses the Importance of Continuous Glucose Monitoring

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that its Symphony(TM) tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasiv…… Read More

02/18/2010 12:00 am
Echo Therapeutics Announces Significant Product Development Milestone: The Completion of Next Generation Electronic Components for Its Revolutionary, Patented Symphony(TM) tCGM System
Company Plans Clinical Trial in the Near Future

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that the Company has made a significant advance in the product design of its Symphony tCGM device and that it has developed its next generation electronic component package. This important advance include…… Read More

02/09/2010 12:00 am
Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc.

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., the Company's Chairman and CEO, will be interviewed on "Steve Crowley's American Scene National Radio" on Tuesday, February 9, 2010 at 9:34 AM ET and Thursday, February 11, 2…… Read More

01/22/2010 12:00 am
Echo Therapeutics Announces Research Initiation by LifeTech Capital

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, is pleased to announce the availability of an independent research report that was issued yesterday with a "Strong Speculative Buy" recommendation and a 12 to 18 month price target of $4.50. The report is authored by Ste…… Read More

01/19/2010 12:00 am
Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc.

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., the Company's Chairman and CEO, will be interviewed on "Steve Crowley's American Scene National Radio" on Wednesday, January 20, 2010 at 9:42 AM ET and Friday January 22, 201…… Read More

01/11/2010 12:00 am
Echo Therapeutics Announces Major Milestone: The Completion of Product Development Work of its Revolutionary, Patented Prelude(TM) SkinPrep System
Company Plans Clinical Trial Testing and Commercialization in Near-Term

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that the Company has completed the product development work for its Prelude SkinPrep System and now has the commercially ready product to be used in final clinical trials.

Echo anticipates that no furthe…… Read More

01/07/2010 12:00 am
Echo Therapeutics to Present at OneMedForum 2010 Emerging Company Finance Conference

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the OneMedPlace Finance Forum 2010 at 11.45 a.m. (PT) on Wednesday, January 13, 2010 at The Sir Fran…… Read More

01/05/2010 12:00 am
Echo Therapeutics CEO Interviewed by Stockgoodies.com
Patrick Mooney Discusses Transformative Year, Development Progress and Growth Strategy

Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, today announced the availability of a recent interview conducted with Chairman and Chief Executive Officer Patrick T. Mooney, M.D. Stockgoodies.com, a G6 Stocks community, will conduct the interview live at 8:30 a.m. E…… Read More

  1. Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference... Read More
  2. Echo Therapeutics Initiates Clinical Study of Its New One-Piece SymphonTM tCGM Biosensor in Type 1 and Type 2 Diabetic Patients... Read More
  3. Echo Therapeutics Announces Positive Results of a Clinical Study Testing SymphonyTM tCGM System in Patients with Type 1 and Type 2 Diabetes... Read More
  4. Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference... Read More
  5. Echo Therapeutics Licenses Needle-free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine... Read More
  6. Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free SymphonyTM Transdermal Continuous Glucose Monitoring System... Read More
  7. Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference... Read More
  8. Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign... Read More
  9. Echo Therapeutics to Present at Prestigious "Innovations in Diabetes" Conference... Read More
  10. Echo Therapeutics to Present at Jessup & Lamont 2009 Growth Stock Conference... Read More
  11. Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference... Read More
  12. Echo Therapeutics Announces Significant Advance in Development of Its One-Piece, Needle Free Symphony tCGM Biosensor... Read More
  1. Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing... Read More
  2. Echo Therapeutics Starts Clinical Study of Its Symphony TM Continuous Transdermal Glucose Monitoring System... Read More
  3. Echo Therapeutics Announces Positive Results with the PreludeTM SkinPrep System, the Next-Generation Skin Permeation Medium for its SymphonyTM Transdermal Continuous Glucose Monitoring System... Read More
  4. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies... Read More
  5. Dr. Anthony P. Furnary Joins Echo Therapeutics Medical Advisory Board... Read More
  6. Echo Therapeutics Announces Agreement for $2,000,000 Debt Financing... Read More
  7. Echo Therapeutics Initiates Clinical Study of Its SymphonyTM Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes... Read More
  8. Echo Therapeutics to Present at RedChip Small-Cap Investor Conference... Read More
  9. Echo Therapeutics Announces Positive Results of a Clinical Study of its SymphonyTM Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes... Read More
  10. Echo Therapeutics to Present Clinical Study Results of Its Symphony Transdermal Continuous Glucose Monitoring System at Annual Diabetes Technology Meeting... Read More
  11. Echo Therapeutics Announces Positive Results from SymphonyTM Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center... Read More
  12. Echo Therapeutics to Present at JMP Securities Healthcare Investor Conference... Read More
  13. Echo Therapeutics to Present at Rodman & Rensha's Annual Global Investment Conference... Read More
  14. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology... Read More
  15. Echo Therapeutics Announces Issuance of New Patent for SymphonyTM Transdermal Continuous Glucose Monitoring System... Read More
  1. Echo Therapeutics Reports Third Quarte 2007 Results... Read More

 

Top